TEIJIN LTD/ JP3544000007 /
2024-07-16 9:30:23 AM | Chg. -0.10 | Volume | Bid10:02:33 AM | Ask10:02:33 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
7.75EUR | -1.27% | 1 Turnover: 7.75 |
7.75Bid Size: 648 | 7.85Ask Size: 634 | 1.51 bill.EUR | - | - |
GlobeNewswire
05-13
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparath...
GlobeNewswire
05-09
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with...
GlobeNewswire
01-31
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for ...
GlobeNewswire
2023-11-29
Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan
Newsfile Corp
2022-11-21
The "Electrification" of the World: Battery Safety and Efficiency Demands Grow Amidst Lofty Global E...
GlobeNewswire
2020-09-09
Radius Health Announces Scientific Presentations on abaloparatide at ASBMR 2020 Annual Meeting